{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"4"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"8"}]}],"title":"Incomplete Response (IR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}],"title":"Partial Response (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Overall Objective Response will be assessed prior to dose-intensive therapy and at the completion of therapy. Complete disappearance of all clinical, radiographic and biochemical (normal AFP and HCG) evidence of disease for a minimum of 4 weeks (CR to chemotherapy). Patients must be free of disease for a minimum of 4 weeks. Partial Response: Complete disappearance of all biochemical evidence of disease in patients without a surgical procedure for a residual radiographic mass. Patients must demonstrate no biochemical recurrence or progression of radiographic masses for a minimum of four weeks (PR to chemotherapy}","groups":[{"description":"Group A: Prior Treatment Limited to \\<= 6 Cycles of Cisplatin","id":"OG000","title":"Group A"},{"description":"Group B: Prior Treatment Limited to \\> 6 Cycles of Cisplatin","id":"OG001","title":"Group B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Objective Response","type":"PRIMARY","unitOfMeasure":"participants"}